anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. At each point it was applied 60 J / cm², for 16 seconds. Three laser's sessions were applied with a time interval of 24 hours between them. GLaserCPPACPF first received the CPPACPF application and then the laser application according to the manufacturer's recommendations. Before initiating laser therapy, the equipment was calibrated with a tester (MMOptics Ltda®, Brazil).

The GCPPACPF volunteers were submitted to the application of the CPPACPF'S containing tooth paste MI Paste Plus™ (Recaldent™, GC América, USA) on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) for 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the desensitizing gel during 20 seconds on each tooth, according to the manufacturer's specifications. GPlacebo followed the same protocol used in GCPPACPF. In addition to the desensitizing treatments, all GCPPACPF and GPlacebo volunteers received the positioning of the laser tip to mimic the light emission produced in GLaser and GLaserCPPACPF. The noise emitted by the laser device was mimic through the sound reproduction of a smartphone application (HD Voice Recorder - iPhone 6s, Apple®, USA).
The disclosure is directed to methods of using Floctafenine, or pharmaceutically acceptable salt of thereof, or derivative thereof, for treatment of patients with coronavirus infection including SARS-CoV-2. This compound is capable of inhibiting SARS-CoV-2 Main protease with highest specificity that allows the highest precision binding to the active site of SARS-CoV-2 Main protease. As a result of this targeted inhibition viral replication is expected to be blocked. That is expected to be a successful treatment of coronavirus infection including SARS-CoV-2. In addition to capability of inhibiting viral replication, Floctafenine is known for its anti inflammatory properties. That is expected to contribute to improving the outcome of subjects with inflammatory response as a result of coronavirus infection including SARS-CoV-2. Drug Repurposing is also expected to reduce healthcare costs given how laborious de novo drug discovery projects have been.
PURPOSE: To perform a systematic review to compare clinical outcomes of hip arthroscopy patients undergoing microfracture (MFx) versus other cartilage repair procedures for chondral lesions of the acetabulum.
METHODS: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines by searching PubMed, the Cochrane Library, and Embase to identify comparative studies that directly compared outcomes between MFx and other cartilage repair procedures for full-thickness chondral lesions of the acetabulum identified during hip arthroscopy. The search phrase used was: hip AND arthroscopy AND microfracture. Patients were evaluated based on reoperation rates and patient-reported outcomes.
RESULTS: Six studies (all Level III evidence) met inclusion criteria, including a total of 202 patients undergoing microfracture (group A) and 327 patients undergoing another cartilage repair procedure (group B). Mean patient age ranged from 35.0 to 45.0 years. Mean follow-up time ranged from 12.0 to 72.0 months. Significantly better patient-reported outcomes (PROs) were found in patients undergoing treatment with bone marrow aspirate concentrate, microfragmented adipose tissue concentrate, autologous matrix-induced chondrogenesis, and a combination of autologous matrix-induced chondrogenesis and bone marrow aspirate concentrate compared with MFx. No studies found significantly better postoperative PROs in group A. The reoperation rate ranged from 0% to 34.6% in group A and 0% to 15.9% in group B. Three of 5 studies reporting on reoperation rate found a significantly greater reoperation rate in group A, with no difference in the other 2 studies.
CONCLUSIONS: The literature on MFx of acetabular chondral lesions is limited and heterogeneous. Based on the available data, MFx alone results in a greater or equivalent reoperation rate and inferior or equivalent PROs compared with other cartilage repair procedures for acetabular chondral lesions in patients with femoroacetabular impingement syndrome.
LEVEL OF EVIDENCE: Level III, systematic review of level III studies.
Conventional group was treated with biofeedback for pelvic floor relaxation and manual therapy to release the tension in the suprapubic, pelvic, and intravaginal areas. The manual therapy consisted of a myofascial trigger point release maneuver using digital pressure and muscle fiber stretching in pain areas. Biofeedback consisted of pelvic floor muscle coordination and relaxation exercises using intravaginal probes. The training program was initiated with 10 fast contractions with 5 seconds of relaxation between them followed by 10 sustained contractions of 5 seconds with 10 seconds of relaxation between them. Finally, one minute of pelvic floor relaxation was performed.
Here we describe the case of a 69-year-old man who was found to have moderate thrombocytopenia and severe splenomegaly during a medical checkup at the age of 67. At the first visit, his white blood cell (WBC) count was 7,400/µl with 80% lymphocytes, and bone marrow aspiration showed 24% atypical lymphocytes. Flow cytometry of atypical lymphocytes was positive for mature T-cell markers, and T-cell clonality was revealed by T-cell receptor gene rearrangement. TCL1 was negative on immunohistochemistry. We diagnosed TCL1-family negative T-cell prolymphocytic leukemia (T-PLL) and employed watchful waiting. Thirty months after diagnosis, the patient developed urinary retention and right lower-limb paresis despite a normal WBC count, and an extradural tumor around the thoracic vertebrae and spinal cord compression were detected. The tumor was diagnosed as extranodal involvement of TCL1-family negative T-PLL, but the patient's general condition deteriorated rapidly, and no treatment was possible. T-PLL is a rare disease characterized by leukocytosis, and the WBC count generally increases with disease progression. Although blood counts are recommended for observation, it is important to keep in mind that the disease may worsen even if blood counts do not change.
Participants in the TAU arm will receive either Cognitive Behavioral Therapy (CBT) or Dialectical Behavior Therapy (DBT), depending on eligibility. CBT will be twice weekly sessions for the first four weeks. From week 4 to week 8, the therapist and client will collaboratively decide whether to have once or twice weekly sessions. From week 8 to week 12, sessions will be weekly. Acute treatment will end after 12 weeks. In DBT, individual sessions will be approximately one hour per week, with optional additional or longer sessions available if deemed clinically necessary, and group sessions will be scheduled for two hours once per week.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a world health issue during the last months, affecting mostly countries with a high metabolic risk, like Mexico. Patients with type 2 diabetes (T2D) have an increased risk of any kind of infection as well as an increased mortality risk. Hyperglycemia has been established as an important predictor of mortality in patients with T2D and SARS-CoV-2. The standard treatment of hyperglycemia in hospitalized patients has been basen on insulin schemes, but recently evidence suggest the utility of some other drugs, reducing the risk of hypoglucemia and increasing the probability of a proper metabolic control. DPP4 enzyme has an ubiquitous distribution and has been considered as a pro-inflammatory enzyme, considering that DPP4 inhibitors could have and anti-inflammatory effect, as it has been shown in different works. The goal os this study is to compare the utility of DPP4 inhibitor as a combination with insulin on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 and hyperglycemia. For this purpose we will randomize patients with SARS-CoV-2 and hyperglycemia to receive either the combination of DPP4i + insulin or insulin alone and will follow al algorithm treatment to define metabolic control as well as prognosis.
This is a Phase 1 dose finding and dose verification study which will be used to determine the dose of S. sonnei 53G that induces the primary outcome in approximately ≥60% of Kenyan adult volunteers. This study will occur in two phases, Phase A (dose-finding) with up to 40 volunteers challenged with 53G and Phase B (dose verification) with N=30 volunteers planned to be administered 53G. Based on previously published data using this model, 1,500 colony-forming units (CFU) will be the dose administered to the first cohort. Dosing of subsequent cohorts will depend on results of the previous cohort. If a lower-than-expected attack rate (AR) occurs, the dose for the next cohort will be increased by 500 CFU. Conversely, if the AR is higher than expected the dose for the next cohort will be decreased by 500 CFU. Cohorts of volunteers will continue to be challenged until either; a dose that reproducibly causes infection in at least 60% of volunteers; safety precludes continuing (\>90% AR at 500 CFU) or futility (an AR of 60% is unable to be achieved, even with a 3000 CFU dose). It may take more or less than 3 dose-finding groups to find the optimal dose for which the primary outcome (shigellosis) is achieved in approximately ≥60% of the volunteers and thus the total number of volunteers enrolled in both phases may be less or more than N=60. Once the optimal dose is established in Phase A, that dose will be carried forward for verification in Phase B. For Phase B, dose verification groups of 30 volunteers (2 cohorts of 15 volunteers per cohort) will be conducted to verify the AR with the chosen dose. The dose finding and verification stages will be done in a staggered fashion in case the dose needs to be adjusted, resulting in approximately 5 cohorts to be enrolled over time. Allocation into the groups will be on "first come first served basis" with no randomization occurring for enrolment in any of the cohorts.
Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime, Merck Canada Inc.). Also, a perforated pessary (Dr. Arabin, cerclage pessary perforated) will be inserted. The pessary will be removed and the progesterone treatment will be stopped at 36 6/7 weeks of gestation.
Techniques are provided for determining classifications based on WSIs. A varied-size feature map is generated for each training WSI by generating a grid of patches for the training WSI, segmenting the training WSI into tissue and non-tissue areas, and converting patches comprising the tissue areas into tensors. Bounding boxes are generated based on the patches comprising tissue areas and segmented into feature map patches. A fixed-size feature map is generated based on a subset of the feature map patches. A classifier model is trained to process fixed-size feature maps corresponding to the training WSIs such that, for each fixed-size feature map, the classifier model is operable to assign a WSI-level tissue or cell morphology classification or regression based on the tensors. A classification engine is configured to use the trained classifier model to determine a WSI-level tissue or cell morphology classification or regression for a test WSI.
<P>PROBLEM TO BE SOLVED: To provide an industrially advantageous method for producing a sphingolipid derivative by which the high-purity sphingolipid derivative can artificially be synthesized in high yield.  <P>SOLUTION: The method for producing the sphingolipid derivative represented by general formula (I) is carried out as follows. A compound having a triisopropylsilyl group is introduced into a compound represented by general formula (II) to provide a compound represented by general formula (III) in which a secondary hydroxy group thereof is protected. The resultant compound is then reacted with a phosphorus-containing compound or a sugar-containing compound to afford a compound represented by general formula (IV). The secondary hydroxy group of the resultant compound is then deprotected to provide the sphingolipid derivative.  <P>COPYRIGHT: (C)2004,JPO
A: Intervention Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Impact® Advanced Recovery: Three times daily for the 5 days just prior to the start of each cycle of chemotherapy. Participants will undergo pre- and post-treatment assessments.
PURPOSE:To provide the titled receptor capable of determining the membrane- bonded tumor antigen and free tumor antigen qualitatively or quantitatively, easily in high sensitivity, by bonding a labeling agent to a T-cell antigen receptor capable of specifically bonding to an antigen. CONSTITUTION:A T-cell antigen receptor derived from a broad tumoricidal killer T-cell clone is bonded with a labeling agent (e.g. fluorescein isothiocyanate or rhodamine which are fluorescent pigments, radioactive <125>I, etc.) to obtain the titled receptor. The tumor antigen on a tumor cell membrane can be identified by adding the receptor to the tumor cell. Furthermore, free tumor antigen can be determined quantitatively and easily in high sensitivity by radioimmunoassay. It can be applied effectively to the qualitative and quantitative determination of virus antigen, bacterial antigen, histocompatibility antigen, etc., in addition to the tumor antigen.
FIELD: organic chemistry. SUBSTANCE: invention relates to new 2-bromo- and 2-nitroxy-derivatives of 3,3- -dibromo-4-oxoazethidines of the general formula (I)   where R 1  and R 2  mean bromine atom; R 2  means the group   where R 4  means hydrogen atom, methyl, benzyl; X means bromine atom or nitroxy-group. 2-Bromo- and 2-nitroxy-derivatives of 3,3-dibromo-4-oxoazethidines are synthesized by reaction of penicillanic acid 1,1-dioxide derivatives of the formula (II)   where R 1  and R 2  mean bromine atom and R 4  means methyl or benzyl with DBN reagent (1,5-diazabicyclo-[3.4.0] -none-5-ene) and obtained sulfinic acid DBN salt or isolated sulfinic acid is subjected for reaction with thionyl chloride. Thionyl chloride is removed by evaporation, obtained residue is passed through column with silica gel and eluted with methylene chloride or any other solvent or obtained residue is dissolved in tetrahydrofurane or in any other suitable solvent followed by reaction with tetrabutylammonium bromide and isolation of a derivative of the formula (I) where R 1  and R 2  are bromine atom; R 3  means the group   where R 4  means hydrogen atom, methyl or benzyl and X means bromine atom. Isolated compound can be subjected for interaction with silver nitrate in isopropanol followed by isolation of derivatives of 2-nitroxy- -3,3-dibromo-4-oxoazethidine. Synthesized compounds are suitable intermediate substances for synthesis of 1-oxapenems and show antitumor activity. Also, invention proposes a method of growth SUPPRESSION of human uterus cervix tumor cells (HeLa) but without effect on human fibroblasts. Invention relates to also new 2-chloro-derivatives of 3,3-dibromo-4-oxoazethidines of the formula (I) where R 1  and R 2  mean bromine atom; R 3  means the group   where R 4  means hydrogen atom or benzyl and X means chloride atom. EFFECT: improved method of synthesis and enhanced tumor cell growth inhibition. 12 cl, 8 ex
<P>PROBLEM TO BE SOLVED: To obtain a nanoparticle, in an aqueous solution, of a concentration similar to concentration of the nanoparticle in the synthesis in an organic solution, without no restrictions from a viewpoint of the use of the nanoparticle in future.  <P>SOLUTION: This nanoparticle contains a hydrophobic component Y(12), a hydrophilic component X(16) and an organic molecular component Z(14). The phase transfer method is to transfer an inorganic colloidal particle from an organic phase to a water phase or an alcohol phase which is immissible with the organic phase, using a phase transfer catalyst bonding the component X and the component Y together. The hydrophobic component Y(12) contains a thiol group and the hydrophilic component X(16) contains a carboxyl group. After completing the phase transfer, the water phase or the alcohol phase is separated from the organic phase.  <P>COPYRIGHT: (C)2009,JPO&INPIT
OBJECTIVES: Tinnitus is one of the irritating symptoms that should be addressed in adolescents. Since tinnitus affects mental health, it is important to treat it. However, identifying the cause of tinnitus is very challenging and the treatment strategies of tinnitus are controversial. The objective of this study was to identify the prevalence of tinnitus in adolescents and systemic diseases as risk factors of adolescent tinnitus to find evidence for new treatment strategies.
MATERIALS AND METHODS: We extracted the subjects and data using the 5th Korea National Health and Nutrition Examination Survey from 2010 to 2012. One thousand five hundred ninety-three adolescents with bilateral normal tympanic membranes and availability of the results of physical, laboratory and audiological examinations, were selected. We evaluated their systemic diseases based on these results and assessed the association of tinnitus with demographic factors, systemic diseases and hearing levels.
RESULTS: The prevalence of tinnitus in Korean adolescents was 21.7%. The hearing level was not associated with tinnitus. Tinnitus was significantly associated with age (p = 0.005), 25(OH)-D level (p = 0.007) and anaemia (p = 0.003). After controlling the other factors, age (p = 0.045), 25(OH)-D level (p = 0.041) and anaemia (p = 0.019) were independently related to tinnitus.
CONCLUSION: Tinnitus in adolescents was significantly associated with age, vitamin D and anaemia. Physicians should consider the higher likelihood of these deficiencies or diseases in adolescent tinnitus patients. Additionally, recognizing these associations may be helpful in developing treatment strategies for adolescent tinnitus.
The super absorbent material (4) is derivatives of cellulose, alginates, polyacrylic or polymethacrylic acid, polyacrylamide, polyvinylpyrrolidone, polyvinyl ether and/or gums with woven are linked to one another other than by weaving in the sheet form, which forms a gel after absorption with the liquid undergoes reduction in external surface (10 %). The volume of housing (3) having a plane base wall (6) with an inclined lateral wall (7) contains the liquid quantity for the gelification. The receptacle (2) comprises a plate is obtained by thermoforming. The super absorbent material having 99 wt.% before impregnation with the liquid. The product in the form of a glove, thimble, mob-cap, hood, boot sock, a sac to be laid around an ear, comprises: a carboxymethyl cellulose derivative (100 %); a self-tan/anti-wrinkle/vitamin C with powdery active ingredient (150 %), which is incorporated into the product by an alternate electric filed; material does not absorb the liquid; and a cavity (16) is placed in the human body. The product appears as a patch or of a mask has cohesion after impregnation by the liquid is non-elastically deformable with an increase in 50% of thickness. The device comprises a closing (5) with a cover, which is fixed at the receptacle by gluing or thermal welding. The depth of housing (3) is higher than the maximum thickness (2-6 mm) of the product. Independent claims are also included for: (1) a kit; and (2) a procedure for cosmetic treatment using the above device.
Traumatic brain injury (TBI) is a global public safety issue that poses a threat to death, characterized by high fatality rates, severe injuries and low recovery rates. There is growing evidence that necroptosis regulates the pathophysiological processes of a variety of diseases, particularly those affecting the central nervous system. Thus, moderate necroptosis inhibition may be helpful in the management of TBI. Receptor-interacting protein kinase (RIP) 3 is a key mediator in the necroptosis, and its absence helps restore the microenvironment at the injured site and improve cognitive impairment after TBI. In this report, we review different domains of RIP3, multiple analyses of necroptosis, and associations between necroptosis and TBI, RIP3, RIP1, and mixed lineage kinase domain-like. Next, we elucidate the potential involvement of RIP3 in TBI and highlight how RIP3 deficiency enhances neuronal function.
BACKGROUND: Humeral nonunions have devastating negative effects on patients' upper extremity function and health-related quality of life. The objective of this study was to identify factors independently associated with 30-day complication, hospital readmission, and reoperation after surgical treatment of humeral nonunions.
MATERIALS AND METHODS: A retrospective case-control study was performed using the American College of Surgeons National Surgical Quality Improvement Program database by querying the Current Procedural Terminology codes for patients who underwent humeral nonunion repair from 2011 to 2020. The study outcomes were 30-day complication, hospital readmission, and reoperation.
RESULTS: Of the 1306 patients in our cohort, 135 patients (10%) developed a complication, 66 patients (5%) were readmitted to the hospital, and 44 patients (3%) underwent reoperation during the 30-day postoperative period. Multivariable logistic regression analysis showed that older age, longer operative time, partially dependent functional status, congestive heart failure, bleeding disorder, and contaminated wound classification were associated with 30-day complication after humeral nonunion repair. Older age and disseminated cancer were associated with 30-day reoperation after humeral nonunion repair. Disseminated cancer was associated with 30-day readmission after humeral nonunion repair.
CONCLUSION: Using a large database over a recent 10-year period, we identified demographic and comorbid factors independently associated with episode of care adverse events after humeral nonunion repair. Patients 50 years or older had approximately three times the incidence of complications, readmissions, and reoperations in the first month after humeral nonunion repair compared with patients younger than 50 years. Our findings are relevant for preoperative risk stratification and counseling. [Orthopedics. 2024;47(4):e181-e187.].
Ingestible compositions comprising a chromic change agent together with methods of making and using them are provided. The chromic change agent alternatively may be associated with the ingestible, such as a packaging material for the ingestible. In response to a triggering event, physical or chemical, the chromic change agent changes color to provide information as to the history of the ingestible, either prior or contemporaneous with use. Depending on the use, the color change agent may be reversible or irreversible. Various solid or liquid ingestible compositions are provided for determining ingestible temperature, storage temperature, user temperature, light exposure, pH change, hydration or solvation change, mechanical stress, and the like, particularly in comestibles. Of particular interest are polydiacetylene polymers that may be formulated to provide compositions having numerous different color transition triggering mechanisms. The invention is also related to other chromic change agents that may be incorporated into ingestibles.
Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.